Diagnosing myasthenic crisis in SARS-CoV-2 infected patients requires adherence to appropriate criteria

With interest we read the article by Delly et al. about a 56 years old female with myasthenia gravis (MG) since 5y for which she received pyridostigmine (240 mg/d), prednisone (40 mg/d), and intravenous immunoglobulins (IVIG, 650 mg/kg within 2d every 2 weeks), and with undetermined mixed connective tissue disease for which she received chloroquine (400 mg/d), who developed myasthenic crisis with respiratory insufficiency during pneumonia due to infection with SARS-CoV-2 [1]. Though the patient received vancomycin, cefepime, and azithromycin and prednisone was increased to 80 mg/d, she lastly had to be intubated and required mechanical ventilation [1].

from Journal of the Neurological Sciences https://ift.tt/305KUPX